US 12,343,472 B2
Powder preparation, cartridge, and device
Shunji Haruta, Kagoshima (JP)
Assigned to Shin Nippon Biomedical Laboratories, Ltd., Kagoshima (JP)
Appl. No. 16/975,701
Filed by Shin Nippon Biomedical Laboratories, Ltd., Kagoshima (JP)
PCT Filed Feb. 7, 2019, PCT No. PCT/JP2019/004331
§ 371(c)(1), (2) Date Aug. 25, 2020,
PCT Pub. No. WO2019/163520, PCT Pub. Date Aug. 29, 2019.
Claims priority of application No. 2018-032498 (JP), filed on Feb. 26, 2018.
Prior Publication US 2020/0405983 A1, Dec. 31, 2020
Int. Cl. A61M 15/08 (2006.01); A61K 9/00 (2006.01); A61K 9/14 (2006.01); A61K 45/06 (2006.01); A61M 11/00 (2006.01); A61M 15/00 (2006.01)
CPC A61M 15/08 (2013.01) [A61K 9/0075 (2013.01); A61K 9/14 (2013.01); A61K 45/06 (2013.01); A61M 11/001 (2014.02); A61M 15/0065 (2013.01); A61M 15/0086 (2013.01); A61M 2202/064 (2013.01)] 16 Claims
OG exemplary drawing
 
1. A method comprising administering a powder preparation to an olfactory region in a nasal cavity,
wherein the powder preparation comprises an active ingredient, the powder preparation having a bulk density of 0.1 to 0.5 g/cm3, and a Hausner ratio of 1.6 to 2.4;
wherein the powder preparation is injected into the nasal cavity at a maximum air pressure of 15 to 80 kPa;
wherein the maximum air pressure is reached at 0 to 30 msec;
wherein the powder preparation is continuously injected at an air pressure of 10 kPa or more for a duration of 20 to 80 msec; and
wherein 20% by weight or more of the active ingredient delivered into the nasal cavity is distributed in the olfactory region.